Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids
- PMID: 11090543
- DOI: 10.1161/01.res.87.11.992
Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids
Abstract
The cytochrome P450-derived epoxyeicosatrienoic acids (EETs) have potent effects on renal vascular reactivity and tubular sodium and water transport; however, the role of these eicosanoids in the pathogenesis of hypertension is controversial. The current study examined the hydrolysis of the EETs to the corresponding dihydroxyeicosatrienoic acids (DHETs) as a mechanism for regulation of EET activity and blood pressure. EET hydrolysis was increased 5- to 54-fold in renal cortical S9 fractions from the spontaneously hypertensive rat (SHR) relative to the normotensive Wistar-Kyoto (WKY) rat. This increase was most significant for the 14,15-EET regioisomer, and there was a clear preference for hydrolysis of 14, 15-EET over the 8,9- and 11,12-EETs. Increased EET hydrolysis was consistent with increased expression of soluble epoxide hydrolase (sEH) in the SHR renal microsomes and cytosol relative to the WKY samples. The urinary excretion of 14,15-DHET was 2.6-fold higher in the SHR than in the WKY rat, confirming increased EET hydrolysis in the SHR in vivo. Blood pressure was decreased 22+/-4 mm Hg (P:<0.01) 6 hours after treatment of SHRs with the selective sEH inhibitor N:, N:'-dicyclohexylurea; this treatment had no effect on blood pressure in the WKY rat. These studies identify sEH as a novel therapeutic target for control of blood pressure. The identification of a potent and selective inhibitor of EET hydrolysis will be invaluable in separating the vascular effects of the EET and DHET eicosanoids.
Similar articles
-
Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats.Toxicol Appl Pharmacol. 2013 Nov 15;273(1):47-57. doi: 10.1016/j.taap.2013.08.012. Epub 2013 Aug 28. Toxicol Appl Pharmacol. 2013. PMID: 23993975
-
Epoxyeicosatrienoic acid pathway in human health and diseases.J Cardiovasc Pharmacol. 2013 Mar;61(3):188-96. doi: 10.1097/FJC.0b013e318273b007. J Cardiovasc Pharmacol. 2013. PMID: 23011468 Review.
-
Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.Am J Physiol Regul Integr Comp Physiol. 2012 Feb 1;302(3):R321-30. doi: 10.1152/ajpregu.00606.2011. Epub 2011 Nov 23. Am J Physiol Regul Integr Comp Physiol. 2012. PMID: 22116511 Review.
-
Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.Am J Physiol Renal Physiol. 2011 Oct;301(4):F765-72. doi: 10.1152/ajprenal.00201.2011. Epub 2011 Jul 13. Am J Physiol Renal Physiol. 2011. PMID: 21753077 Free PMC article.
-
Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney.Mol Pharmacol. 2000 May;57(5):1011-20. Mol Pharmacol. 2000. PMID: 10779386
Cited by
-
Regulation of soluble epoxide hydrolase in renal-associated diseases: insights from potential mechanisms to clinical researches.Front Endocrinol (Lausanne). 2024 Feb 15;15:1304547. doi: 10.3389/fendo.2024.1304547. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38425758 Free PMC article. Review.
-
How Robust Is the Ligand Binding Transition State?J Am Chem Soc. 2023 Nov 22;145(46):25318-25331. doi: 10.1021/jacs.3c08940. Epub 2023 Nov 9. J Am Chem Soc. 2023. PMID: 37943667 Free PMC article.
-
Inflammation, lipids, and pain in vulvar disease.Pharmacol Ther. 2023 Aug;248:108467. doi: 10.1016/j.pharmthera.2023.108467. Epub 2023 Jun 5. Pharmacol Ther. 2023. PMID: 37285943 Review.
-
Soluble epoxide hydrolase inhibitor promotes the healing of oral ulcers.Clinics (Sao Paulo). 2023 May 4;78:100208. doi: 10.1016/j.clinsp.2023.100208. eCollection 2023. Clinics (Sao Paulo). 2023. PMID: 37148830 Free PMC article.
-
Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics.Phenomics. 2022 Oct 27;3(1):34-49. doi: 10.1007/s43657-022-00069-8. eCollection 2023 Feb. Phenomics. 2022. PMID: 36939801 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical